tirzepatide surmount 5 For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Zepbound Shows Superior Weight Loss
Description
Starting Jan.1, 2026, Pennsylvania will limit GLP1 weightloss drugs under Medicaid threatening access for thousands of lowincome patients.
Learn why patients stop treatment and how clinicians can improve persistence and outcomes.
Receive physician-guided injections and schedule a complimentary consultation today.
For some members, long-term use is the right answer
Exceedingly short half-life (12 min) of GLP-1 limits its therapeutic applicability, and the implication of its new variants is under question
it offers a promising opportun...
